4//SEC Filing
Ring Christine 4
Accession 0001817199-25-000005
CIK 0001549595other
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 6:02 PM ET
Size
21.0 KB
Accession
0001817199-25-000005
Insider Transaction Report
Form 4
Ring Christine
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-30+3,750→ 51,683 total - Exercise/Conversion
Restricted Stock Units
2025-10-30−3,750→ 22,500 totalExercise: $0.00→ Common Stock (3,750 underlying) - Exercise/Conversion
Common Stock
2025-10-30+1,924→ 45,933 total - Exercise/Conversion
Common Stock
2025-10-30+2,000→ 47,933 total - Exercise/Conversion
Restricted Stock Units
2025-10-30−2,858→ 28,584 totalExercise: $0.00→ Common Stock (2,858 underlying) - Exercise/Conversion
Restricted Stock Units
2025-10-30−1,924→ 1,925 totalExercise: $0.00→ Common Stock (1,924 underlying) - Exercise/Conversion
Restricted Stock Units
2025-10-30−2,000→ 4,000 totalExercise: $0.00→ Common Stock (2,000 underlying) - Exercise/Conversion
Common Stock
2025-10-30+2,858→ 54,541 total - Sale
Common Stock
2025-10-30$12.80/sh−3,644$46,631→ 50,897 total
Footnotes (8)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $12.68 and the highest price at which shares were sold was $12.89. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F4]The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
- [F5]RSUs do not expire; they either vest or are canceled prior to the vest date.
- [F6]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F7]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F8]The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Documents
Issuer
Nurix Therapeutics, Inc.
CIK 0001549595
Entity typeother
Related Parties
1- filerCIK 0001817199
Filing Metadata
- Form type
- 4
- Filed
- Oct 29, 8:00 PM ET
- Accepted
- Oct 30, 6:02 PM ET
- Size
- 21.0 KB